(Q62812962)
Statements
Phase II Trial of Daratumumab for Transplant-Eligible Multiple Myeloma Patients (English)
0 references
9 April 2018
0 references
1 April 2019
0 references
50
0 references
18 year
0 references
64 year
0 references